GlassScriptPhysician profile
Daniel Yj Kim
NPI 1295766483
$4,854.04
in general payments reported to CMS, 2019-2025
23 companies · $558 in 2025
The $558 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,842 · 2020: $309 · 2022: $248 · 2023: $982 · 2024: $914 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,454.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $871.88 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $556.17 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $524.56 | 2022-2025 | |
| Lundbeck LLC | $498.62 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $459.40 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $278.24 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $257.82 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $200.16 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $173.26 | 2022-2025 | Auvelity |
| Allergan, INC. | $161.76 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $147.19 | 2019-2020 | |
| Bausch Health US, LLC | $132.62 | 2019-2024 | Aplenzin, Wellbutrin |
| Shire North American Group INC | $109.92 | 2019 | |
| Sunovion Pharmaceuticals INC. | $109.78 | 2019-2020 | |
| Almatica Pharma LLC | $103.74 | 2023-2024 | Loreev Xr, Sertraline Hcl |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $103.72 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $37.91 | 2025 | Cobenfy |
| Alkermes, INC. | $27.39 | 2025 | Lybalvi |
| Biogen, INC. | $23.17 | 2024 | Zurzuvae |
| Vanda Pharmaceuticals INC. | $22.75 | 2025 | Fanapt |
| Tris Pharma INC | $20.67 | 2023 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $19.35 | 2020 | |
| Avanir Pharmaceuticals, INC. | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.